Literature DB >> 32165026

Community pharmacy delivered PrEP to STOP HIV transmission: An opportunity NOT to miss!

Maria I Lopez, Robert M Grant, Betty J Dong.   

Abstract

In the United States, 1.1 million persons are living with human immunodeficiency virus (HIV), and approximately 37,800 new infections occur annually. Ending the HIV epidemic requires reducing HIV transmissions by 90% within the next 10 years and requires expanded HIV testing, antivirals for persons infected with HIV, and scale-up of pre-exposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) to prevent new infections. Community pharmacies are widely accessible and employ highly trained health care professionals on-site who can initiate PrEP and PEP. Recommendations are offered to implement a community pharmacy PrEP program. Pharmacy, government, and HIV prevention leaders must be prepared to support and promote transformative changes, including (1) modification or expansion of existing state-specific scope of practice to initiate PrEP and PEP, (2) encouraging pharmacist education about PrEP and PEP, (3) identification and screening of candidates for PrEP eligibility, (4) incorporating pharmacy laboratory ordering and monitoring logistics, (5) adjusting workflow and ensuring confidential spaces for sensitive discussions, and (6) addressing reimbursement to maintain pharmacist-delivered PrEP and PEP programs. HIV disproportionately affects minority communities and younger individuals who may not be engaged in the health care system. Community pharmacies are accessible and can help increase PrEP use. Expansion of community pharmacy PrEP programs are needed to help end the HIV epidemic. Implementation of PrEP requires adaptation of the pharmacy profession to support incorporation of PrEP in a community pharmacy. Endorsement and support of community pharmacists are needed to implement PrEP to increase HIV prevention efforts and expand pharmacists' scope of practice.
Copyright © 2020 American Pharmacists Association®. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32165026     DOI: 10.1016/j.japh.2020.01.026

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  5 in total

Review 1.  Toward Greater Pre-exposure Prophylaxis Equity: Increasing Provision and Uptake for Black and Hispanic/Latino Individuals in the U.S.

Authors:  Robert A Bonacci; Dawn K Smith; Bisola O Ojikutu
Journal:  Am J Prev Med       Date:  2021-11       Impact factor: 5.043

Review 2.  Ending the HIV epidemic for all, not just some: structural racism as a fundamental but overlooked social-structural determinant of the US HIV epidemic.

Authors:  Lisa Bowleg; Arianne N Malekzadeh; Mary Mbaba; Cheriko A Boone
Journal:  Curr Opin HIV AIDS       Date:  2022-03-01       Impact factor: 4.061

Review 3.  Pharmacy-Based Interventions to Increase Use of HIV Pre-exposure Prophylaxis in the United States: A Scoping Review.

Authors:  Alice Zhao; Derek T Dangerfield; Amy Nunn; Rupa Patel; Jason E Farley; Chinenye C Ugoji; Lorraine T Dean
Journal:  AIDS Behav       Date:  2021-10-20

4.  PrEP distribution in pharmacies: a systematic review.

Authors:  Caitlin E Kennedy; Ping Teresa Yeh; Kaitlyn Atkins; Laura Ferguson; Rachel Baggaley; Manjulaa Narasimhan
Journal:  BMJ Open       Date:  2022-02-21       Impact factor: 3.006

5.  A comparison of attitudes and knowledge of pre-exposure prophylaxis (PrEP) between hospital and Key Population Led Health Service providers: Lessons for Thailand's Universal Health Coverage implementation.

Authors:  Ajaree Rayanakorn; Sineenart Chautrakarn; Kannikar Intawong; Chonlisa Chariyalertsak; Porntip Khemngern; Debra Olson; Suwat Chariyalertsak
Journal:  PLoS One       Date:  2022-05-12       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.